A patient with chronic kidney disease exhibits signs of fluid overload and electrolyte imbalances, including hyperkalemia and mild metabolic acidosis. The patient's blood pressure remains elevated despite adherence to antihypertensive medication. Which of the following nursing interventions should be prioritized to address these clinical findings?

A) Administer a higher dose of furosemide to enhance fluid excretion.

B) Educate the patient on reducing dietary potassium intake to manage hyperkalemia.

C) Recommend the addition of a calcium channel blocker to better control blood pressure.

D) Initiate a bicarbonate infusion to correct metabolic acidosis.

A patient with chronic kidney disease presents with signs of fluid overload, elevated blood pressure, and electrolyte imbalances, including hyperkalemia. The healthcare team is considering adjustments to the patient's medication regimen. Which nursing intervention should be prioritized to address these issues?

B) Administer furosemide to reduce fluid overload and monitor electrolyte levels closely.

A) Increase the dose of the patient's current antihypertensive medication.

B) Administer furosemide to reduce fluid overload and monitor electrolyte levels closely.

C) Initiate a potassium-sparing diuretic to manage electrolyte imbalances.

D) Recommend an increase in dietary potassium to balance the electrolyte disturbance.

A patient with a history of hypertension and fluid overload is being treated with furosemide and an ACE inhibitor. Recent lab results show a serum potassium level of 6.1 mEq/L. Which of the following interventions should the nurse anticipate to address the hyperkalemia while considering the current medication regimen?

B) Discontinue the ACE inhibitor and initiate a potassium binder

A) Decrease the dose of furosemide and monitor renal function

B) Discontinue the ACE inhibitor and initiate a potassium binder

C) Encourage increased dietary intake of potassium-rich foods

D) Increase the dose of the ACE inhibitor to improve blood pressure control

A patient with chronic kidney disease and hypertension is being treated with furosemide and an ACE inhibitor. The patient presents with hyperkalemia, a blood pressure of 140/90 mmHg, and stabilized serum creatinine levels. Which nursing intervention should the nurse prioritize to address the hyperkalemia while considering the patient's need for blood pressure management?

B) Administer a potassium binder and monitor the patient's cardiac rhythm.

A) Discontinue the ACE inhibitor and start the patient on a beta-blocker.

B) Administer a potassium binder and monitor the patient's cardiac rhythm.

C) Increase the dose of furosemide to enhance potassium excretion.

D) Encourage the patient to increase fluid intake to dilute serum potassium levels.

A patient with chronic kidney disease is being treated for hyperkalemia with sodium polystyrene sulfonate and dietary potassium restriction. Despite these interventions, the patient's potassium levels remain elevated, and the ECG shows peaked T-waves. Which of the following actions should the nurse anticipate the healthcare provider will take next to manage the patient's hyperkalemia?

A) Administer intravenous calcium gluconate

B) Increase the dose of the current potassium binder

D) Discontinue the ACE inhibitor immediately

A patient with chronic kidney disease (CKD) is being treated for hyperkalemia with sodium polystyrene sulfonate and dietary modifications. Recent lab results show a decrease in GFR from 28 mL/min/1.73m² to 24 mL/min/1.73m², and the patient reports mild fatigue and muscle cramps. Considering these findings, which nursing intervention is most appropriate to address the patient's symptoms and potential renal function decline?

D) Monitor hydration status and adjust fluid intake to support renal perfusion.

A) Encourage increased dietary potassium to address muscle cramps.

B) Recommend discontinuing the ACE inhibitor to improve renal function.

C) Increase the frequency of sodium polystyrene sulfonate administration.

D) Monitor hydration status and adjust fluid intake to support renal perfusion.

A patient with chronic kidney disease presents with hyperkalemia and a declining glomerular filtration rate (GFR). The current management includes sodium polystyrene sulfonate and dietary modifications. Given the new decline in GFR and the patient's symptoms of fatigue and muscle cramps, which nursing action should be prioritized?

C) Collaborate with the healthcare provider to evaluate the necessity of continuing the ACE inhibitor.

A) Discontinue the sodium polystyrene sulfonate to prevent further electrolyte imbalance.

B) Monitor the patient’s cardiac status and electrolyte levels closely while maintaining the current regimen.

C) Collaborate with the healthcare provider to evaluate the necessity of continuing the ACE inhibitor.

D) Increase the patient's diuretic dosage to enhance renal excretion and address hyperkalemia.

A patient with chronic kidney disease presents with increased serum creatinine and elevated phosphorus levels. The nephrology team has recommended adjusting the medication regimen to prevent further renal decline. Which nursing intervention is most appropriate to implement based on the patient's current condition?

B) Administer phosphate binders with meals to reduce phosphorus absorption.

A) Encourage the patient to increase fluid intake to promote renal perfusion.

B) Administer phosphate binders with meals to reduce phosphorus absorption.

C) Withhold ACE inhibitor medication to prevent hyperkalemia.

D) Instruct the patient to avoid high-potassium foods to manage electrolyte balance.

A patient with chronic kidney disease (CKD) and a recent decline in renal function is being evaluated. The diagnostic results show an elevated creatinine level and serum phosphorus, with an ultrasound revealing increased renal parenchymal echogenicity. The clinical team is considering adjusting the patient's medication regimen. Which of the following nursing interventions is most appropriate to address the patient's current condition?

B) Educate the patient on low-phosphorus dietary choices.

A) Encourage increased fluid intake to promote renal perfusion.

B) Educate the patient on low-phosphorus dietary choices.

C) Advise discontinuation of the ACE inhibitor to prevent further renal damage.

D) Suggest the use of diuretics to manage potential fluid overload.

CKD - Nursing Case Study

Pathophysiology

• Primary mechanism: Chronic kidney disease (CKD) primarily involves the gradual loss of nephrons, leading to impaired glomerular filtration rate (GFR). This results in the accumulation of waste products like urea and creatinine in the blood, causing systemic toxicity and electrolyte imbalances.

• Secondary mechanism: As nephron loss progresses, surviving nephrons undergo hyperfiltration and hypertrophy to compensate, which further damages renal structures due to increased intraglomerular pressure. This accelerates nephron loss and fibrosis, perpetuating a cycle of damage.

• Key complication: The resulting diminished renal function often leads to hypertension due to fluid overload and increased renin-angiotensin-aldosterone system (RAAS) activity, exacerbating cardiovascular risk and further kidney damage.

Patient Profile

Demographics:

58-year-old male, retired factory worker

History:

• Key past medical history: Hypertension, Type 2 Diabetes, Stage 3 Chronic Kidney Disease

• Current medications: Lisinopril, Metformin, Atorvastatin, Furosemide

• Allergies: Penicillin

Current Presentation:

• Chief complaint: Fatigue and swelling in legs

• Key symptoms: Increased fatigue, peripheral edema, shortness of breath on exertion, nocturia

• Vital signs: Blood pressure 150/95 mmHg, heart rate 88 bpm, respiratory rate 20 breaths per minute, temperature 98.6°F, oxygen saturation 94% on room air

Section 1

As the clinical team conducts an initial assessment, they note that the patient exhibits signs of worsening fluid retention, evident from the pitting edema in his lower extremities and mild periorbital edema. His weight has increased by 5 pounds over the past week, suggesting fluid overload. Auscultation of the lungs reveals bilateral crackles at the bases, indicating pulmonary congestion, a common complication of advancing chronic kidney disease. The patient's blood pressure remains elevated at 150/95 mmHg despite compliance with prescribed antihypertensive medication, suggesting possible medication resistance or the need for dosage adjustment.

Laboratory results show a decline in renal function, with serum creatinine rising to 2.2 mg/dL from a previous value of 1.8 mg/dL, and a decrease in estimated glomerular filtration rate (eGFR) to 40 mL/min/1.73m², down from 45 mL/min/1.73m². Electrolyte imbalances are noted, with hyperkalemia present at 5.8 mEq/L and mild metabolic acidosis with a bicarbonate level of 19 mEq/L. These findings suggest further renal deterioration, likely exacerbated by uncontrolled hypertension and possibly underlying diabetic nephropathy.

In light of these developments, the healthcare team must engage in clinical reasoning to address the immediate concerns of fluid overload and electrolyte imbalances. Adjustments to the patient's medication regimen, such as increasing the dose of furosemide or adding another antihypertensive agent, may be considered to improve blood pressure control and address fluid retention. Additionally, dietary modifications, including sodium and potassium restrictions, should be emphasized to mitigate electrolyte disturbances. These interventions aim to stabilize the patient's condition and prevent progression to more severe stages of kidney disease. The team will closely monitor the patient's response to these interventions, ready to reassess and adjust the care plan as necessary.

Section 2

A week after implementing the adjustments to the patient's care plan, the clinical team conducts a follow-up assessment to evaluate the response to interventions aimed at managing fluid overload and hypertension. The patient reports a slight reduction in swelling, and upon examination, there is a noticeable decrease in pitting edema of the lower extremities. Periorbital edema has also diminished. However, auscultation of the lungs still reveals persistent crackles at the bases, albeit less pronounced than before, indicating partial improvement in pulmonary congestion.

The patient's blood pressure has shown some improvement, now reading 140/90 mmHg, following an increased dose of furosemide and the addition of an ACE inhibitor to the regimen. However, laboratory results present new challenges; while serum creatinine has stabilized at 2.1 mg/dL, suggesting a temporary halt in renal decline, hyperkalemia has worsened, with potassium levels now at 6.1 mEq/L. This elevation raises concerns about the potential exacerbation of cardiac complications, necessitating immediate attention.

The healthcare team must engage in further clinical reasoning to address the persistent hyperkalemia. Consideration may be given to initiating a potassium binder or increasing dietary restrictions on potassium. Additionally, the team will evaluate the risk-benefit ratio of continuing the ACE inhibitor, as it may contribute to the elevated potassium levels. Close monitoring of cardiac function and electrolyte balance becomes paramount, and the team prepares to introduce telemetry if necessary. These decisions aim to optimize patient outcomes by balancing the need for blood pressure control with the management of potential complications associated with electrolyte imbalances. The team remains vigilant, ready to adjust the care plan based on the patient's ongoing response and any new developments.

Section 3

The clinical team convenes to address the issue of worsening hyperkalemia, considering both pharmacologic and dietary interventions. After a thorough review of the patient's current medications and dietary intake, the decision is made to initiate treatment with a potassium binder, such as sodium polystyrene sulfonate, to facilitate the excretion of excess potassium. Concurrently, the dietitian works closely with the patient to further restrict dietary potassium, emphasizing low-potassium food choices and educating on hidden sources of potassium in the diet. This dual approach aims to mitigate the immediate risk of cardiac complications while maintaining the benefits of the current antihypertensive regimen.

During this period, the patient undergoes additional diagnostic tests to assess cardiac function and ensure stability. An electrocardiogram (ECG) reveals peaked T-waves, consistent with hyperkalemia, but no other significant arrhythmias, suggesting that interventions are timely. The clinical team decides to closely monitor the patient on telemetry, allowing for real-time observation of any potential cardiac changes. Furthermore, serum electrolytes are checked frequently to assess the effectiveness of the potassium-lowering strategies. The team remains alert to the possibility of needing to adjust or discontinue the ACE inhibitor if hyperkalemia persists or worsens despite these measures.

As the patient continues to receive care, the next steps will focus on evaluating the response to these interventions over the coming days. The team will monitor for any new complications such as further fluid imbalances or shifts in renal function. This ongoing assessment will guide any necessary adjustments to the care plan, ensuring that both blood pressure and electrolyte levels are managed effectively to optimize patient outcomes. The patient's journey reflects the complexity of balancing multiple aspects of chronic kidney disease management, requiring continuous clinical reasoning and adaptability from the healthcare team.

Section 4

As the clinical team continues to monitor the patient, the initial response to the potassium-lowering interventions shows promising signs. Over the first 48 hours, serial serum potassium levels begin to gradually decrease from a concerning 6.2 mEq/L down to 5.4 mEq/L, indicating that the combination of sodium polystyrene sulfonate and dietary modifications is effectively reducing hyperkalemia. The patient's ECG, while still displaying peaked T-waves, shows no progression to more severe arrhythmias, suggesting the immediate cardiac risk is being mitigated. The patient's blood pressure remains stable at 130/85 mmHg, and no significant fluid overload is noted on physical examination, maintaining an overall positive outlook on the current management strategy.

However, as the days progress, new diagnostic results reveal a slight decline in renal function, with the patient's glomerular filtration rate (GFR) dropping from 28 mL/min/1.73m² to 24 mL/min/1.73m². This change prompts the clinical team to consider potential causes, including the possible nephrotoxic effects of the current medication regimen or further progression of the underlying chronic kidney disease. Concurrently, the patient reports experiencing mild fatigue and occasional muscle cramps, symptoms that may correlate with the electrolyte shifts and reduced kidney function.

These developments necessitate a reassessment of the patient's treatment plan. The clinical team deliberates the risks and benefits of continuing the ACE inhibitor in the context of both hypertension control and its contribution to hyperkalemia. They also consider the need for additional nephroprotective strategies, such as optimizing hydration status and possibly adjusting diuretic therapy to balance fluid and electrolyte management. This critical juncture in the patient's care underscores the importance of ongoing clinical reasoning and adaptability, as the team strives to maintain stability while preventing further renal deterioration and addressing the patient's emerging symptoms.

Section 5

New Diagnostic Results:

As the clinical team continues to evaluate the patient's condition, further diagnostic tests are conducted to gain a deeper understanding of the changes in renal function and to identify any emerging complications. A repeat comprehensive metabolic panel reveals that, in addition to the previously noted decline in GFR to 24 mL/min/1.73m², the patient's creatinine level has increased from 2.5 mg/dL to 3.0 mg/dL. This rise in creatinine suggests a worsening of renal function, prompting concerns about possible acute kidney injury superimposed on the existing chronic kidney disease. Additionally, the patient's serum phosphorus level is noted to be elevated at 5.6 mg/dL, which may contribute to the mild muscle cramps the patient has been experiencing.

An ultrasound of the kidneys is performed to assess for any structural changes or obstructions that could be contributing to the decline in renal function. The imaging reveals no evidence of hydronephrosis or renal stones, but it does show a slight increase in renal parenchymal echogenicity, consistent with chronic kidney changes. This finding aligns with the progression of CKD but does not explain the acute decline in function, suggesting that other factors, such as medication effects or dehydration, may be playing a role.

These results lead the clinical team to consider a revision of the patient's medication regimen, particularly the potential nephrotoxic effects of the current drugs. The nephrology consult recommends reducing the dose of the ACE inhibitor to mitigate hyperkalemia while ensuring that blood pressure remains controlled. Additionally, the team decides to initiate phosphate binders to address the elevated phosphorus levels and to closely monitor the patient's hydration status. These strategic adjustments aim to stabilize renal function, manage electrolyte imbalances, and alleviate the patient's symptoms, all while maintaining a fine balance between effective treatment and prevention of further complications.